The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Subscribe To Our Newsletter & Stay Updated
